scholarly journals Pharmacotherapy of migraine prevention based on the assessment of headache

2020 ◽  
Vol 63 (10) ◽  
pp. 644-649
Author(s):  
Hee-Ji Im ◽  
Soo-Jin Cho
Keyword(s):  
Quality Of Life ◽  
Preventive Intervention ◽  
Beta Blockers ◽  
Position Statement ◽  
Episodic Migraine ◽  
Reproductive Age ◽  
Migraine Prevention ◽  
Improve Quality ◽  
Preventive Medication

Migraine as a recurrent, relapsing, and chronic disease is one of the most disabling disorders globally. Most patients are women in their reproductive age and their migraines are classified as episodic migraine. Although less than half of the episodic and most chronic migraineurs require preventive intervention, early discontinuation rates are high, owing to poor tolerability and insufficient awareness about migraine. This article aims to review the recent update of migraine prevention based on the practice guidelines for the prevention of episodic migraine published by the Korea Headache Society and the position statement of the American Headache Society in 2019. The goal of migraine prevention is to reduce migraine attack frequency by at least 50 %, the number of migraine days, and the attack severity to ultimately improve quality of life. The guidelines recommend considering the initiation of preventive medication when recurring migraines significantly interfere with daily life or when acute treatment is contraindicated or inappropriate. Preventive medications should be determined based on various qualified assessments. Pharmacologic treatments are recommended for migraine prophylaxis include antidepressant (amitriptyline), anti-epileptic drugs (topiramate, divalproex sodium), beta-blockers (propranolol, metoprolol), calcium channel blocker (flunarizine), and intramuscular injection of onabotulinumtoxin A. Furthermore subcutaneous or intravenous injection of calcitonin gene-related peptide monoclonal antibodies was recently approved as a new therapy for migraine prevention. Migraine is a chronic debilitating disorder. The initiation of evidence-based preventive management is necessary and management methods should be individually selected to improve quality of life.

scholarly journals Pretreatment fertility counseling and fertility preservation improve quality of life in reproductive age women with cancer

Cancer ◽  
2011 ◽  
Vol 118 (6) ◽  
pp. 1710-1717 ◽  
Author(s):  
Joseph M. Letourneau ◽  
Erin E. Ebbel ◽  
Patricia P. Katz ◽  
Audra Katz ◽  
Wei Z. Ai ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Fertility Preservation ◽  
Reproductive Age ◽  
Improve Quality ◽  
Reproductive Age Women ◽  
Fertility Counseling

scholarly journals Efficacy of galcanezumab in patients with migraine and history of failure to 3–4 preventive medication categories: subgroup analysis from CONQUER study

2021 ◽  
Vol 22 (1) ◽  
Author(s):  
Rose Okonkwo ◽  
Antje Tockhorn-Heidenreich ◽  
Chad Stroud ◽  
Marie-Ange Paget ◽  
Manjit S. Matharu ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Subgroup Analysis ◽  
Migraine Headache ◽  
Response Rate ◽  
Maximum Tolerated Dose ◽  
Episodic Migraine ◽  
Patient Functioning ◽  
Preventive Medication ◽  
History Of

Abstract Background Chronic migraine (CM) and episodic migraine (EM) are associated with substantial headache-related disability, poor quality of life and global societal burden. In this subgroup analysis from the CONQUER study, we report efficacy outcomes from a pre-specified analysis of galcanezumab versus placebo in patients with CM or EM and 3–4 prior preventive medication category failures due to inadequate efficacy (after at least 2 months at maximum tolerated dose), or safety or tolerability reasons. The patient population is of particular interest due to evidence of decreased quality of life and increased economic burden among patients with migraine that is inadequately managed and is of interest to decision-makers globally. Methods Key outcomes included overall mean change from baseline in monthly migraine headache days and proportions of patients achieving ≥30% (CM), ≥50%, and ≥ 75% reduction (response rates) in monthly migraine headache days across Months 1–3. Patient functioning and disability were evaluated at Month 3. Results Of the 462 randomized patients, 186 (40.3%) had a history of 3–4 preventive category failures. Galcanezumab versus placebo resulted in significantly (P ≤ .001) larger overall mean reduction in monthly migraine headache days (total: − 5.49 versus − 1.03; CM: − 6.70 versus − 1.56; EM: − 3.64 versus − 0.65). Similarly, the ≥50% response rate was significantly (P ≤ .001) higher with galcanezumab versus placebo (total: 41.0 versus 12.7; CM: 41.5 versus 8.4; EM: 41.1 versus 16.5). In the CM group, the ≥30% response rate was significantly higher in the galcanezumab group than the placebo group (CM, 57.5 versus 19.8, P ≤ .0001) as was the ≥75% response rate (13.3 versus 2.6, P ≤ .05). Galcanezumab also resulted in significant (P < .0001) improvements in patient functioning and reductions in disability. Conclusions Galcanezumab was effective in a difficult-to-treat population of patients with CM or EM who had failed 3–4 prior preventive medication categories. Trial registration CONQUER. Clinicaltrials.gov identifier: NCT03559257.

Widening the horizons: Information space of the library for the blind as the resource to improve quality of life of visually impaired people

2020 ◽  
Author(s):  
Olga Novikova ◽  
Keyword(s):  
Quality Of Life ◽  
Continuing Education ◽  
Visually Impaired ◽  
Information Space ◽  
Advanced Training ◽  
Improve Quality ◽  
Visually Impaired People ◽  
Impaired People ◽  
Special Library

The special library acts as the cultural and educational center for visually impaired people, and as the center for continuing education. The multifunctional performance of the library is substantiated. The joint projects accomplished in cooperation with theatres and museums and aimed at integrating the visually impaired people into the society are described. Advanced training projects for the library professionals accomplished in 2018 are discussed.

Sign in / Sign up

Export Citation Format

Share Document